Protalex (OTCMKTS:PRTX) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
Insider and Institutional Ownership
0.2% of Protalex shares are held by institutional investors. Comparatively, 3.9% of Cleveland BioLabs shares are held by institutional investors. 80.0% of Protalex shares are held by insiders. Comparatively, 1.9% of Cleveland BioLabs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Protalex has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Protalex and Cleveland BioLabs, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Protalex and Cleveland BioLabs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Protalex and Cleveland BioLabs’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cleveland BioLabs||$1.14 million||14.57||-$3.61 million||N/A||N/A|
Cleveland BioLabs has higher revenue and earnings than Protalex.
Cleveland BioLabs beats Protalex on 5 of the 8 factors compared between the two stocks.
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
About Cleveland BioLabs
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Receive News & Ratings for Protalex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex and related companies with MarketBeat.com's FREE daily email newsletter.